Serial Number | 97697528 |
Word Mark | CELLERITAS |
Filing Date | Wednesday, November 30, 2022 |
Status | 731 - SECOND EXTENSION - GRANTED |
Status Date | Monday, October 21, 2024 |
Registration Number | 0000000 |
Registration Date | NOT AVAILABLE |
Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
Published for Opposition Date | Tuesday, October 17, 2023 |
Goods and Services | Manufacturing services for others in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals, plasmid DNA production; manufacturing services for others in the fields of mammalian cell banks, plasmids, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; manufacturing process consulting |
Goods and Services | Research and development services in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; consulting services in the fields of research and development for gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; research and development of new products for others; process development services in the nature of research and development of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; scientific research and technical research services, namely, production of cell lines for others using lentivirus technology; scientific research and technical research services relating to producing, assaying and purifying recombinant or manipulated lentivirus; Scientific and technical consulting services relating to producing, assaying, and purifying adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; advisory services relating to research and development of gene therapy products and biopharmaceuticals; manufacturing support services for others, namely, cGMP (Current Good Manufacturing Practice) quality control testing in support of biopharmaceutical development and manufacturing; quality control for others; quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; material testing; product quality testing; scientific laboratory services; scientific research; research and development in the field of gene therapy acceleration, vector genome copy titers, droplet digital polymerase chain reaction (PCR) and digital polymerase chain reaction (PCR), mass spectrometry, capsid characterization, bioassays, plasmid DNA, and analytics testing in the field of genes and gene therapy |
International Class | 040 - Treatment of materials. |
US Class Codes | 100, 103, 106 |
Class Status Code | 6 - Active |
Class Status Date | Thursday, December 22, 2022 |
Primary Code | 040 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
US Class Codes | 100, 101 |
Class Status Code | 6 - Active |
Class Status Date | Thursday, December 22, 2022 |
Primary Code | 042 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
Party Name | CENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC |
Party Type | 20 - Owner at Publication |
Legal Entity Type | 16 - Limited Liability Company |
Address | KING OF PRUSSIA, PA 19406 |
Party Name | CENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC |
Party Type | 10 - Original Applicant |
Legal Entity Type | 16 - Limited Liability Company |
Address | KING OF PRUSSIA, PA 19406 |
Event Date | Event Description |
Saturday, December 3, 2022 | NEW APPLICATION ENTERED |
Thursday, December 22, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Saturday, September 9, 2023 | ASSIGNED TO EXAMINER |
Thursday, September 14, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
Wednesday, September 27, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
Tuesday, October 17, 2023 | PUBLISHED FOR OPPOSITION |
Tuesday, October 17, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
Tuesday, December 12, 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
Thursday, May 9, 2024 | SOU EXTENSION 1 GRANTED |
Thursday, May 9, 2024 | SOU TEAS EXTENSION RECEIVED |
Thursday, May 9, 2024 | SOU EXTENSION 1 FILED |
Friday, May 10, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Monday, October 21, 2024 | SOU TEAS EXTENSION RECEIVED |
Monday, October 21, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Monday, October 21, 2024 | SOU EXTENSION 2 FILED |
Monday, October 21, 2024 | SOU EXTENSION 2 GRANTED |